|

Positive Association of US-FLI With the Severity of CAD

RECRUITINGSponsored by Chongqing Medical University
Actively Recruiting
SponsorChongqing Medical University
Started2022-07-01
Est. completion2025-04-28
Eligibility
Age18 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06541132

Summary

As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.

Eligibility

Age: 18 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients older than 18 years old
* Patients underwent ICA due to chest pain, chest tightness or other reasons in our hospital from August 2022 to December 2023 were included in our study

Exclusion Criteria:

* Incomplete clinical data
* previous coronary stent implantation
* no abdominal ultrasound examination
* poor ultrasound image quality
* congenital heart disease
* tumor
* thyroid diseases and infectious diseases

Conditions6

Coronary Artery Disease of Significant Bypass GraftHeart DiseaseLiver DiseaseMetabolic Dysfunction-associated Fatty Liver DiseaseSYNTAX ScoreUltrasonography

Browse More Trials

Heart Disease trialsLiver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.